A range of opposition rises to Nebraska Gov. Jim Pillen's budget bills
Child care advocates were among those testifying at a public hearing Tuesday on Gov. Jim Pillen's two-year budget request. (Courtesy of First Five Nebraska)
LINCOLN — From child care to tourism to banking, housing and wildlife, advocates of various Nebraska industries spoke in opposition Tuesday of Gov. Jim Pillen budget bills.
Sixteen people voiced objections to the Legislature's Appropriations Committee, while Pillen's state budget administrator Neil Sullivan defended recommendations aimed in part at addressing a $432 million state shortfall over the next two years.
Mark McHargue of the Nebraska Farm Bureau spoke in a 'neutral' capacity, saying he was not making a blanket endorsement but was in full support of the governor's effort to put more state funds toward property tax relief.
People who wrote in opposition to Legislative Bills 260 through 264, all introduced on Pillen's behalf by Speaker John Arch of La Vista, totaled 135. Three wrote in support of the proposals that were the topic of a combined public hearing at the State Capitol.
Tuesday's hearing — the first of several opportunities the public will have over the next few weeks to speak on the state budget — offered a glimpse at budget-balancing challenges the governor and lawmakers face from diverse interests.
Drew Larsen, representing Pheasants Forever and Quail Forever, and Katie Torpy of Ducks Unlimited and the Nature Conservancy, were among several who objected to Pillen's recommendation to redirect funds from the Nebraska Environmental Trust to other purposes such as park improvements.
They said such diversions betray the intent of Nebraska voters, who in 1992 approved a state lottery. A portion of lottery proceeds was to go to the Trust, which awards grants on a competitive basis to projects that 'conserve, enhance and restore the natural environments of Nebraska.'
'We urge the Legislature to reject these bills and stand with Nebraska voters, conservationists and communities in protecting the integrity of the Trust,' Torpy said.
Carol Bodeen, representing associations for the Nebraska Housing Developers and Nebraska Economic Developers, stood up against redirecting $8 million from the Affordable Housing Trust Fund and $2 million from the Rural Workforce Housing Investment Fund to the general fund.
Benjamin Dennis, representing the Nebraska Advocacy Group (NAG) and a group of rural telecom and broadband providers, stood against the repeal of the Broadband Bridge Act he said was created by the Legislature in 2021 to provide $20 million annually in grants to improve access to Internet service.
Meghan Chaffee, representing the Nemaha County Hospital in Auburn, objected to reducing by $1.5 million a year the Rural Health Provider Incentive Program, which helps reduce education debt of qualified health professionals who agree to practice in Nebraska.
Also among testifiers was Jen Goettemoeller Wendl, representing First Five Nebraska, which opposes the transfer of $3.25 million from the Early Childhood Education Endowment Cash fund to the Education Future Fund.
She said the Early Childhood fund was created in 2006, and built on a private donation match that established a $60 million endowment. It is 'problematic, possibly not legally permissible,' Goettemoeller Wendl said, to remove money from the fund and transfer it elsewhere.
'Eroding trust in public private partnerships is not in the state's best interest,' she said.
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Trump aides want Texas to redraw its congressional maps to boost the GOP. What would that mean?
This coverage is made possible through Votebeat, a nonpartisan news organization covering local election administration and voting access. Sign up for Votebeat Texas' free newsletters here. Republicans representing Texas in Congress are considering this week whether to push their state Legislature to take the unusual step of redrawing district lines to shore up the GOP's advantage in the U.S. House. But the contours of the plan, including whether Gov. Greg Abbott would call a special session of the Legislature to redraw the maps, remain largely uncertain. The idea is being driven by President Donald Trump's political advisers, who want to draw up new maps that would give Republicans a better chance to flip seats currently held by Democrats, according to two GOP congressional aides familiar with the matter. That proposal, which would involve shifting GOP voters from safely red districts into neighboring blue ones, is aimed at safeguarding Republicans' thin majority in Congress, where they control the lower chamber, 220-212. The redistricting proposal, and the Trump team's role in pushing it, was first reported by The New York Times Monday. Without a Republican majority in Congress, Trump's legislative agenda would likely stall, and the president could face investigations from newly empowered Democratic committee chairs intent on scrutinizing the White House. Here's what we know about the plan so far: On Capitol Hill, members of the Texas GOP delegation huddled Monday night to discuss the prospect of reshaping their districts. Most of the 25-member group expressed reluctance about the idea, citing concerns about jeopardizing their districts in next year's midterms if the new maps overextended the GOP's advantage, according to the two GOP aides, who spoke on the condition of anonymity to discuss the private deliberations. Rep. Jodey Arrington, R-Lubbock, was skeptical of the idea. 'We just recently worked on the new maps,' Arrington told The Texas Tribune. To reopen the process, he said, 'there'd have to be a significant benefit to our state.' The delegation has yet to be presented with mockups of new maps, two aides said. Each state's political maps must be redrawn once a decade, after each round of the U.S. census, to account for population growth and ensure every congressional and legislative district has roughly the same number of people. Texas lawmakers last overhauled their district lines in 2021. There's no federal law that prohibits states from redrawing district maps midcycle, said Justin Levitt, an election law professor at Loyola Marymount University and a former deputy assistant attorney general in the Department of Justice's civil rights division. Laws around the timing to redraw congressional and state district maps vary by state. In Texas, the state constitution doesn't specify timing, so the redrawing of maps is left to the discretion of the governor and the Legislature. Lawmakers gaveled out of their 140-day regular session last week, meaning they would need to be called back for a special session to change the state's political maps. Abbott has the sole authority to order overtime sessions and decide what lawmakers are allowed to consider. A trial is underway in El Paso in a long-running challenge to the state legislative and congressional district maps Texas drew after the 2020 U.S. Census. If Texas redraws its congressional maps, state officials would then ask the court to toss the claims challenging those districts 'that no longer exist,' Levitt said. The portion of the case over the state legislative district maps would continue. If the judge agrees, then both parties would have to file new legal claims for the updated maps. It isn't clear how much maps could change, but voters could find themselves in new districts, and Levitt said redrawing the lines in the middle of the redistricting cycle is a bad idea. 'If the people of Texas think that their representatives have done a bad job, then when the [district] lines change, they're not voting on those representatives anymore,' Levitt said. 'New people are voting on those representatives.' The National Democratic Redistricting Committee, Democrats' national arm for contesting state GOP mapmaking, said the proposal to expand Republicans' stronghold in Texas was 'yet another example of Trump trying to suppress votes in order to hold onto power.' 'Texas's congressional map is already being sued for violating the Voting Rights Act because it diminishes the voting power of the state's fast-growing Latino population,' John Bisognano, president of the NDRC said. 'To draw an even more extreme gerrymander would only assure that the barrage of legal challenges against Texas will continue.' When Republicans in charge of the Legislature redrew the district lines after the 2020 census, they focused on reinforcing their political support in districts already controlled by the GOP. This redistricting proposal would likely take a different approach. As things stand, Republicans hold 25 of the state's 38 congressional seats. Democrats hold 12 seats and are expected to regain control of Texas' one vacant seat in a special election this fall. Most of Texas' GOP-controlled districts lean heavily Republican: In last year's election, 24 of those 25 seats were carried by a Republican victor who received at least 60% of the vote or ran unopposed. The exception was U.S. Rep. Monica De La Cruz, R-Edinburg, who captured 57% of the vote and won by a comfortable 14-point margin. With little competition to speak of, The Times reported, Trump's political advisers believe at least some of those districts could bear the loss of GOP voters who would be reshuffled into neighboring, Democratic-held districts — giving Republican hopefuls a better chance to flip those seats from blue to red. The party in control of the White House frequently loses seats during midterm cycles, and Trump's team is likely looking to offset potential GOP losses in other states and improve the odds of holding on to a narrow House majority. Incumbent Republicans, though, don't love the idea of sacrificing a comfortable race in a safe district for the possibility of picking up a few seats, according to GOP aides. In 2003, after Texas Republicans initially left it up to the courts to draw new lines following the 2000 census, then-U.S. House Majority Leader Tom DeLay, a Sugar Land Republican, embarked instead on a bold course of action to consolidate GOP power in the state. He, along with his Republican allies, redrew the lines as the opening salvo to a multistate redistricting plan aimed at accumulating power for his party in states across the country. Enraged by the power play, Democrats fled the state, depriving the Texas House of the quorum it needed to function. The rebels eventually relented under threat of arrest, a rare power in the Texas Constitution used to compel absent members back to return to Austin when the Legislature is in session. The lines were then redrawn, cementing the GOP majority the delegation has enjoyed in Washington for the past two decades. However, what's at play this time is different than in the early 2000s, when Republicans had a newfound majority in the Legislature and had a number of vulnerable Democratic incumbents they could pick off. Now, Republicans have been entrenched in the majority for decades and will have to answer the question of whether there's really more to gain, said Kareem Crayton, the vice president of the Brennan Center for Justice's Washington office. 'That's the tradeoff. You can do that too much so that you actually make them so competitive that the other side wins,' Crayton said. 'That's always a danger.' Texas Republicans are planning to reconvene Thursday to continue discussing the plan, according to Rep. Beth Van Duyne, R-Irving, and Rep. Wesley Hunt, R-Houston, who said they will attend the meeting. Members of Trump's political team are also expected to attend, according to Hunt and two GOP congressional aides familiar with the matter. Natalia Contreras is a reporter for Votebeat in partnership with the Texas Tribune. She's based in Corpus Christi. Contact Natalia at ncontreras@ Disclosure: New York Times has been a financial supporter of The Texas Tribune, a nonprofit, nonpartisan news organization that is funded in part by donations from members, foundations and corporate sponsors. Financial supporters play no role in the Tribune's journalism. Find a complete list of them here. Big news: 20 more speakers join the TribFest lineup! New additions include Margaret Spellings, former U.S. secretary of education and CEO of the Bipartisan Policy Center; Michael Curry, former presiding bishop and primate of The Episcopal Church; Beto O'Rourke, former U.S. Representative, D-El Paso; Joe Lonsdale, entrepreneur, founder and managing partner at 8VC; and Katie Phang, journalist and trial lawyer. Get tickets. TribFest 2025 is presented by JPMorganChase.
Yahoo
4 hours ago
- Yahoo
U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer
Approval follows Priority Review and is supported by the robust TRUST clinical program, in which IBTROZI treatment demonstrated high, durable response rates and brain-penetrant efficacy across different lines of therapy The safety and tolerability of IBTROZI have been well established in the pivotal program, with one of the largest safety datasets in ROS1+ NSCLC showing a favorable and consistent profile Company to host conference call tomorrow, June 12 at 7:30 a.m. EDT NEW YORK, June 11, 2025--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved IBTROZI™ (taletrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). IBTROZI is a highly selective, next-generation oral ROS1 tyrosine kinase inhibitor (TKI) designed to address some of the outstanding challenges of treating ROS1+ NSCLC. It has demonstrated high response rates with durable benefit and intracranial activity and is generally well tolerated, providing a new treatment option for patients with advanced ROS1+ NSCLC. "The FDA approval of IBTROZI marks a major milestone in the evolution of targeted therapy for advanced ROS1-positive NSCLC," said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. "We believe one of the greatest threats to ROS1-positive lung cancer patients is disease progression, especially in the first-line setting. In pivotal trials, IBTROZI delivered high response rates with sustained durability—truly meaningful benefits for patients. With its clinically proven efficacy and safety profile, we believe IBTROZI has the potential to become a new standard for what targeted therapies can achieve in this type of lung cancer. With approvals for IBTROZI now in the U.S. and China, and additional global filings underway, we remain committed to delivering innovative therapies that help patients stay ahead of their disease." ROS1+ NSCLC is a rare and aggressive form of lung cancer, accounting for approximately 2% of new NSCLC cases, or about 3,000 new diagnoses of advanced disease annually in the U.S. The median age at diagnosis for patients with this type of lung cancer is approximately 50 years old, and the disease is more likely to occur in people who have never smoked. Brain metastases are common and a leading cause of disease progression and mortality in this population. "For people living with advanced ROS1-positive lung cancer, who tend to be diagnosed at a younger age, having another treatment option can make a real difference for them and their loved ones," said Janet Freeman-Daily, Co-Founder and President of The ROS1ders. "The approval of this new targeted therapy is a meaningful step forward for the advanced ROS1+ lung cancer community and offers hope for patients facing the added challenge of cancer spreading to the brain." The FDA approval of IBTROZI is supported by one of the largest global clinical trial programs in ROS1+ NSCLC to date, with over 300 patients enrolled in the pivotal TRUST-I and TRUST-II studies. In TRUST-I, IBTROZI achieved a confirmed overall response rate (cORR) of 90% in TKI-naïve patients. These findings were reinforced by the TRUST-II results, with a cORR of 85% in TKI-naïve patients. The median duration of response (DOR) was not yet reached for either trial, based on a cutoff date that is nearly five months later than that of the pooled TRUST-I and TRUST-II analysis published in April in the Journal of Clinical Oncology. For TRUST-I, with a median follow-up for responses of 40 months, the longest DOR was observed at 46.9 months and ongoing. For TRUST-II, with a median follow-up for responses of 19 months, the longest DOR was observed at 30.4 months and ongoing as of October 2024. Given the single-arm nature of the TRUST clinical studies, median progression-free survival (PFS) is not provided in the label. Across the pivotal studies, consistent results were also observed among patients who were previously treated with a ROS1 TKI (TKI-pretreated). In TRUST-I, treatment with IBTROZI achieved a cORR of 52% and median DOR of 13.2 months for TKI-pretreated patients, with median follow-up for responses of 33 months. In TRUST-II, treatment with IBTROZI achieved a cORR of 62%, and as of October 2024 the median DOR was 19.4 months in these patients, with a median follow-up for responses of 19 months. Brain metastases are among the most common and devastating complications in advanced ROS1+ NSCLC. IBTROZI was designed to penetrate the central nervous system (CNS) and has demonstrated consistent intracranial responses in patients with measurable brain metastases at baseline. An intracranial response was achieved in 73% of TKI-naive patients (11/15) and 63% of TKI-pretreated patients (15/24). "Patients living with advanced ROS1+ non-small cell lung cancer and their healthcare providers are in need of new treatment options," added Nathan Pennell, M.D., Ph.D., TRUST study investigator and Professor of Medicine at the Cleveland Clinic. "IBTROZI's durability of response and ability to effectively penetrate the brain, coupled with a well-characterized and manageable safety profile, further addresses these critical needs for patients. I believe this now-approved therapy offers providers and patients a promising new option for the treatment of advanced ROS1+ non-small cell lung cancer." Dr. Pennell is a compensated member of Nuvation Bio's advisory committee. IBTROZI was generally well-tolerated, with most adverse events being low grade, transient and manageable. Patients infrequently (7%) discontinued treatment due to treatment-emergent adverse events (TEAEs). The most common adverse reactions (≥20%) included diarrhea (64%), nausea (47%), vomiting (43%), dizziness (22%), rash (22%), constipation (21%), and fatigue (20%). Overall, the majority of CNS events were mild to moderate (~90%) and resolved within days, and dose modifications due to these events were low (~5%). Approximately 90% of reported cases of dizziness were Grade 1 (mild) and transient. Liver enzyme elevations (AST 87%/ALT 85%) and QT prolongation (19%) were manageable with standard monitoring and dose modifications. IBTROZI is approved as a 600 mg once-daily oral dose, supported by a half-life of approximately 66 hours and broad tissue distribution, including the brain, enabling sustained systemic and CNS exposure. Nuvation Bio also announced the launch of NuvationConnect, a program designed to support patients prescribed IBTROZI. The program will offer financial assistance, access to resources and personalized support for eligible patients. Prescribers can learn more at or by calling 1-877-NUV-CON1 (1-877-688-2661). Conference Call & Business Update Nuvation Bio will host a conference call on June 12, 2025 at 7:30 a.m. EDT / 4:30 a.m. PDT, where company executives will provide an overview of the FDA approval of IBTROZI and our plans to now bring this medicine to patients. As a reminder to investors, the approval, together with the first commercial sale, makes the funding secured from Sagard Healthcare Partners in March fully available to the company. Nuvation Bio expects that this finances the launch of IBTROZI in full and provides further resources to continue advancing our pipeline in areas of unmet need. Investors and the general public are invited to register and listen to a live webcast of the event through the company website at Those unable to register can access the live conference call by dialing +1 833-470-1428 (U.S. toll-free) and entering access code 783971. A replay of the event will be available shortly after the conclusion. About ROS1+ NSCLC Each year, more than one million people globally are diagnosed with non-small cell lung cancer (NSCLC), the most common form of lung cancer. It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease. About 35% of patients newly diagnosed with metastatic ROS1+ NSCLC have tumors that have spread to their brain. The brain is also the most common site of disease progression, with about 50% of previously treated patients developing CNS metastases. Despite recent progress for patients with ROS1+ NSCLC, there remains a need for more effective and tolerable treatment options. About IBTROZI IBTROZI is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor therapy approved for the treatment of adult patients with advanced ROS1-positive non-small cell lung cancer. Learn more at About the TRUST Clinical Program The TRUST clinical program evaluating IBTROZI for the treatment of adult patients with advanced ROS1+ NSCLC included two Phase 2 single-arm pivotal studies: TRUST-I (NCT04395677) in China, which enrolled 173 patients, and TRUST-II (NCT04919811), a global study, which enrolled 164 patients. The primary endpoint of these registrational studies is confirmed objective response rate (cORR) as assessed by an independent review committee (IRC). Key secondary endpoints include intracranial cORR, duration of response, progression-free survival, and safety. Indication IBTROZI is indicated for the treatment of adult patients with locally advanced or metastatic ROS1+ non-small cell lung cancer (NSCLC). IMPORTANT SAFETY INFORMATION FOR IBTROZITM (taletrectinib) WARNINGS AND PRECAUTIONS Hepatotoxicity: Hepatotoxicity, including drug-induced liver injury and fatal adverse reactions, can occur. 88% of patients experienced increased AST, including 10% Grade 3/4. 85% of patients experienced increased ALT, including 13% Grade 3/4. Fatal liver events occurred in 0.6% of patients. Median time to first onset of AST or ALT elevation was 15 days (range: 3 days to 20.8 months). Increased AST or ALT each led to dose interruption in 7% of patients and dose reduction in 5% and 9% of patients, respectively. Permanent discontinuation was caused by increased AST, ALT, or bilirubin each in 0.3% and by hepatotoxicity in 0.6% of patients. Concurrent elevations in AST or ALT ≥3 times the ULN and total bilirubin ≥2 times the ULN, with normal alkaline phosphatase, occurred in 0.6% of patients. Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life-threatening, or fatal ILD or pneumonitis can occur. ILD/pneumonitis occurred in 2.3% of patients, including 1.1% Grade 3/4. One fatal ILD case occurred at the 400 mg daily dose. Median time to first onset of ILD/pneumonitis was 3.8 months (range: 12 days to 11.8 months). ILD/pneumonitis led to dose interruption in 1.1% of patients, dose reduction in 0.6% of patients, and permanent discontinuation in 0.6% of patients. QTc Interval Prolongation: QTc interval prolongation can occur, which can increase the risk for ventricular tachyarrhythmias (e.g., torsades de pointes) or sudden death. IBTROZI prolongs the QTc interval in a concentration-dependent manner. In patients who received IBTROZI and underwent at least one post baseline ECG, QTcF increase of >60 msec compared to baseline and QTcF >500 msec occurred in 13% and 2.6% of patients, respectively. 3.4% of patients experienced Grade ≥3. Median time from first dose of IBTROZI to onset of ECG QT prolongation was 22 days (range: 1 day to 38.7 months). Dose interruption and dose reduction each occurred in 2.8% of patients. Significant QTc interval prolongation may occur when IBTROZI is taken with food, strong and moderate CYP3A inhibitors, and/or drugs with a known potential to prolong QTc. Administer IBTROZI on an empty stomach. Avoid concomitant use with strong and moderate CYP3A inhibitors and/or drugs with a known potential to prolong QTc. Hyperuricemia: Hyperuricemia can occur and was reported in 14% of patients, with 16% of these requiring urate-lowering medication without pre-existing gout or hyperuricemia. 0.3% of patients experienced Grade ≥3. Median time to first onset was 2.1 months (range: 7 days to 35.8 months). Dose interruption occurred in 0.3% of patients. Myalgia with Creatine Phosphokinase (CPK) Elevation: Myalgia with or without CPK elevation can occur. Myalgia occurred in 10% of patients. Median time to first onset was 11 days (range: 2 days to 10 months). Concurrent myalgia with increased CPK within a 7-day time period occurred in 0.9% of patients. Dose interruption occurred in 0.3% of patients with myalgia and concurrent CPK elevation. Skeletal Fractures: IBTROZI can increase the risk of fractures. ROS1 inhibitors as a class have been associated with skeletal fractures. 3.4% of patients experienced fractures, including 1.4% Grade 3. Some fractures occurred in the setting of a fall or other predisposing factors. Median time to first onset of fracture was 10.7 months (range: 26 days to 29.1 months). Dose interruption occurred in 0.3% of patients. Embryo-Fetal Toxicity: Based on literature, animal studies, and its mechanism of action, IBTROZI can cause fetal harm when administered to a pregnant woman. ADVERSE REACTIONS Among patients who received IBTROZI, the most frequently reported adverse reactions (≥20%) were diarrhea (64%), nausea (47%), vomiting (43%), dizziness (22%), rash (22%), constipation (21%), and fatigue (20%). The most frequently reported Grade 3/4 laboratory abnormalities (≥5%) were increased ALT (13%), increased AST (10%), decreased neutrophils (5%), and increased creatine phosphokinase (5%). DRUG INTERACTIONS Strong and Moderate CYP3A Inhibitors/CYP3A Inducers and Drugs that Prolong the QTc Interval: Avoid concomitant use. Gastric Acid Reducing Agents: Avoid concomitant use with PPIs and H2 receptor antagonists. If an acid-reducing agent cannot be avoided, administer locally acting antacids at least 2 hours before or 2 hours after taking IBTROZI. OTHER CONSIDERATIONS Pregnancy: Please see important information in Warnings and Precautions under Embryo-Fetal Toxicity. Lactation: Advise women not to breastfeed during treatment and for 3 weeks after the last dose. Effect on Fertility: Based on findings in animals, IBTROZI may impair fertility in males and females. The effects on animal fertility were reversible. Pediatric Use: The safety and effectiveness of IBTROZI in pediatric patients has not been established. Photosensitivity: IBTROZI can cause photosensitivity. Advise patients to minimize sun exposure and to use sun protection, including broad-spectrum sunscreen, during treatment and for at least 5 days after discontinuation. Please see accompanying full Prescribing Information. About Nuvation Bio Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment by developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes IBTROZI (taletrectinib), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor for glioma; NUV-1511, an innovative drug-drug conjugate (DDC) designed for targeted cancer treatment; and NUV-868, a BD2-selective BET inhibitor. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit or follow the company on LinkedIn and X (@nuvationbioinc). Forward-Looking Statements Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, our expectations regarding IBTROZI's therapeutic potential in advanced ROS1+ NSCLC and its potential to become a new standard of care. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from those anticipated by the forward-looking statements, including but not limited to the challenges associated with conducting drug discovery and initiating or conducting clinical studies due to, among other things, difficulties or delays in the regulatory process, enrolling subjects or manufacturing or acquiring necessary products; the emergence or worsening of adverse events or other undesirable side effects; risks associated with preliminary and interim data, which may not be representative of more mature data; and competitive developments. Risks and uncertainties facing Nuvation Bio are described more fully in its Form 10-Q filed with the SEC on May 7, 2025 under the heading "Risk Factors," and other documents that Nuvation Bio has filed or will file with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release. View source version on Contacts Media and Investor ContactsNuvation Bio Investor Contact ir@ Nuvation Bio Media Contact media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Boston Globe
4 hours ago
- Boston Globe
Big Beautiful Bill would ban regulating AI
How did they give away the future of American workers to tech executives? Buried in President Trump's Advertisement Iin Massachusetts, the Republicans' ban would block the State House from considering legislation that would safeguard our fundamental rights. Labor unions, led by the Massachusetts AFL-CIO, and community members have come together to urge the Legislature to pass an act fostering artificial intelligence responsibility, known as the FAIR Act. Advertisement The bill would establish needed guardrails around the use of AI and similar technologies by employers and in the workplace. It would restrict the use of AI-driven worker surveillance tools, many of which are already being used, and prevent employers from relying solely on automatic decision-making systems in hiring, firing, or promotion. With workers increasingly being asked to incorporate AI into their everyday work, this legislation would also establish strong anti-retaliation protections and worker autonomy provisions. If AI tools are to be used for good, we need meaningful human oversight and worker input at every step of their implementation. Preventing states like Massachusetts from considering policy like the FAIR Act would halt community-based momentum and leave workers and their families exposed to the unchecked harms of AI. This kind of giveaway for tech billionaires is the exact opposite of what Americans want from Congress. are wary of how US companies develop and use AI. But congressional Republicans are not listening to workers. Instead, they follow Elon Musk and the other Big Tech executives who want to make Washington, D.C. the next Silicon Valley and hope you won't notice the single section in Trump's bill that lines their pockets and strips you of democracy until 2035. Advertisement Trump urged House Republicans to pass the bill with the AI ban in it. But there is one more hurdle to the president's agenda ahead — the Senate. Senators must now decide whether they will stand with the interests of workers and everyday people or the interests of Big Tech billionaires. The line between tech innovation and tech domination will be drawn not in Washington, but in the workplaces, schools, and sectors where AI transforms our lives, for good and bad. It is the job of state and local representatives to adapt to these changes and pass regulations that make sense for their communities — if only Republicans don't stifle democracy first.
